Australia's largest stock trading and investment forum Australia's #1 stock forum

Day Trader’s Weekend Aftermarket Lounge 22-24 Nov 2019, page-158

First 158 Last

Share
Profile

Follow
dhirst

52 Posts.

1

25/11/19

06:51

Post #: 41605439
Share

Originally posted by Patterns: ↑

@dhirst The two red lines at the top are the supply level where there are so many unfilled sell orders that price has been turned sharply lower. This is a place where buyers can get trapped as overwheming sell orders spear prices lower. The blue box is where the price contracts and is no good for traders to make money. The red box is the ecpansion phase where traders get whipsawed and lose money so is also best avoided. The green box which extends usually from curren t price to the supply level is the safest and best area for traders to trade but ideally exit juzt prior to getting to the supply level. Check out Sam Seiden for supply and demand trading videoreson youtube. Most of the charts consist of filled orders but the supply level shows where instiutional unfilled sell orders are and demand levels show where unfilled instiutional buy orders are on a chart.

Expand

@Patterns, thanks for the explanation, and the time you put into posting your charts.
dave
Upvote

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 2 more messages in this thread...

First 158 Last